All In Biotech

Drug Trial Radar · NCT02555852

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis

Last checked: Nov 19, 2026Latest source record: Sep 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,238,504

Actual

Start

Sep 2011

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Drug Safety and Effectiveness Network, Canada; Canadian Institutes of Health Research (CIHR)
First posted
Sep 22, 2015

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.

Conditions

  • Gastroesophageal Reflux Disease (GERD)
  • Community-acquired Pneumonia

Interventions

  • esomeprazoleDrug

    Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.

  • omeprazoleDrug

    Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.

  • pantoprazoleDrug

    Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.

  • lansoprazoleDrug

    Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.

  • rabeprazoleDrug

    Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.

  • cimetidineDrug

    Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.

  • ranitidineDrug

    Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.

  • famotidineDrug

    Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.

  • nizatidineDrug

    Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.

  • niperotidineDrug

    Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.

  • roxatidineDrug

    Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.

  • ranitidine bismuth citrateDrug

    Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.

  • lafutidineDrug

    Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.

  • cimetidine combinationsDrug

    Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.

  • famotidine combinationsDrug

    Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospitalization for Community-Acquired Pneumonia (HCAP)Time frame: Patients will be followed from the date of study cohort entry until HCAP, censoring, or for up to 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lady Davis Institute for Medical Research, Jewish General Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.